BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 9315095)

  • 1. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
    Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
    Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
    Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
    Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
    Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
    Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM
    Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells.
    Virtanen SS; Sandholm J; Yegutkin G; Kalervo Väänänen H; Härkönen PL
    Cell Biol Int; 2010 Aug; 34(8):815-26. PubMed ID: 20446922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
    Adnane J; Bizouarn FA; Chen Z; Ohkanda J; Hamilton AD; Munoz-Antonia T; Sebti SM
    Oncogene; 2000 Nov; 19(48):5525-33. PubMed ID: 11114730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
    J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.